Insight Molecular Diagnostics (IMDX) risk factors, FY2025 10-K

Risks Related to Our Capital Resources

1. 01We have incurred operating losses since inception, and we do not know if we will attain profitability31% rewritten
2. 02We have historically been dependent upon outside financing capital to fund our operations and until such time as our revenues are sufficient to finance our operating expenses, we may need to issue additional equity or debt securities to raise the capital needed to pay our operating expenses
3. 03We may incur significant cash payment and common stock issuance obligations under our agreements arising from our investments in IGI and Chronix

Risks Related to Our Business Operations

1. 04Our revenues in the near term will depend on our ability to commercialize a small number of diagnostic tests
2. 05The research and development work we are doing is costly, time consuming, and uncertain as to its results40% rewritten
3. 06Increased competition from, and technological advances by, our competitors could negatively affect our operating resultsNew
4. 07Sales of our diagnostic tests could be adversely impacted by the reluctance of physicians to adopt the use of our tests and by the availability of competing diagnostic tests73% rewritten
5. 08We have limited capital, marketing, sales, and regulatory compliance resources for the commercialization of our diagnostic tests
6. 09We may face technology transfer challenges and expenses in adding new tests to our portfolio and in expanding our reach into new geographical areas on new instrument platforms
7. 10If our laboratory facilities become damaged or inoperable, or we are required to vacate any facility, our ability to provide services and pursue our research and development and commercialization efforts may be jeopardized
8. 11There is a limited number of manufacturers of molecular diagnostic testing equipment and related chemical reagents necessary for the provision of our diagnostic tests
9. 12If we fail to enter into and maintain successful strategic alliances for diagnostic tests that we elect to co-develop, co-market, or out-license, we may have to reduce or delay our diagnostic test development or increase our expenditures
10. 13We are, and may become, dependent on collaborations to develop and commercialize our diagnostic test candidates and to provide the manufacturing, regulatory compliance, sales, marketing and distribution capabilities required for the success of our business
11. 14Our business could be adversely affected if we lose the services of the key personnel upon whom we depend
12. 15Our business and operations could suffer in the event of system failures47% rewritten
13. 16Security breaches and other disruptions could compromise our information and expose us to liability, and could cause our business and reputation to suffer
14. 17Failure of our internal control over financial reporting could harm our business and financial results
15. 18We are subject to laws and regulations governing corruption, which may require us to develop, maintain, and implement costly compliance programs
16. 19We may become subject to litigation, which could harm our stock price, business, results of operations and financial condition25% rewritten
17. 20We may undertake strategic acquisitions in the future, and difficulties integrating such acquisitions could damage our ability to achieve or sustain profitability
18. 21Our business could be adversely impacted by inflation53% rewritten

Risks Related to Our Industry

1. 22While we believe our LDTs are within the scope of the FDA’s enforcement discretion policy, and therefore not required to obtain clearance or approval before commercialization, the FDA may attempt to regulate LDTs in the future, which could lead to LDT product development delays and increased costsNew
2. 23We will need to obtain FDA and other regulatory approvals for any IVDs that we may develop in order to market those IVD tests, and we may not be able to obtain those regulatory approvals in a timely manner or at all28% rewritten
3. 24The FDA can withdraw approval of an FDA regulated product if problems ariseNew
4. 25Clinical trial failures can occur at any stage of the testing and we may experience numerous unforeseen events during, or as a result of, the clinical trial process that could delay or prevent commercialization of our current or future diagnostic tests
5. 26Inability or unwillingness of medical investigators to follow our clinical protocols
6. 27Changes in healthcare laws and policies may have a material adverse effect on our financial condition, results of operations and cash flows26% rewritten
7. 28Because of certain Medicare billing policies, we may not receive complete reimbursement for tests provided to Medicare patients
8. 29Long payment cycles of Medicare, Medicaid and other third-party payers, or other payment delays, could hurt our cash flows and increase our need for working capital
9. 30Private health insurance company policies may deny coverage or limit reimbursement for the performance of our diagnostic tests
10. 31We will be required to comply with federal and state laws governing the privacy of health information, and any failure to comply with these laws could result in material criminal and civil penalties
11. 32Tariff policies and potential countermeasures could increase our costs and disrupt our global supply chain, which could negatively impact the results of our operations

Risks Related to Intellectual Property

1. 33We rely on patents and trade secrets, and our financial success will depend, in part, on our ability to obtain commercially valuable patent claims, protect our intellectual property rights and operate without infringing upon the proprietary rights of others
2. 34We may not be able to obtain patent protection for our diagnostic tests if our pending U.S. patent applications are found to be directed to unpatentable subject matter
3. 35Changes to the patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our diagnostic tests
4. 36Other companies or organizations may challenge our patent rights or may assert patent rights that prevent us from developing and commercializing our diagnostic tests
5. 37If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected, and our business would be harmed
6. 38We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful
7. 39We may not be able to enforce our intellectual property rights throughout the world
8. 40If we are sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our diagnostic tests
9. 41Failure to adequately protect, or disputes relating to, trademarks or patents, could harm our business
10. 42Patent terms may be inadequate to protect our competitive position on our diagnostic tests for an adequate amount of time
11. 43Obtaining and maintaining patent protection depends on compliance with various procedures and other requirements, and our patent protection could be reduced or eliminated in case of non-compliance with these requirements

Risks Related to Our Common Stock

1. 44The trading price of our common stock is highly volatile, and purchasers of our common stock could incur substantial lossesNew
2. 45intellectual property, product liability or other litigation against usNew
3. 46Because we do not pay dividends, our stock may not be a suitable investment for anyone who needs to earn dividend income
4. 47Securities analysts may not initiate coverage or continue to cover our common stock, and this may have a negative impact on the market price of our shares
5. 48You may experience dilution of your ownership interests if we issue additional shares of common stock or preferred stock23% rewritten
6. 49We are a “smaller reporting company” under the SEC’s disclosure rules and have elected to comply with the reduced disclosure requirements applicable to smaller reporting companies
7. 50Failure to establish and maintain adequate finance infrastructure and accounting systems and controls could impair our ability to comply with the financial reporting and internal controls requirements for publicly traded companiesNew
8. 51Failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a delisting of our common stockNew